Key Highlights
- Profusa (PFSA) shares jumped over 173% following the company’s announcement of a letter of intent to purchase PanOmics, a cutting-edge next-generation sequencing diagnostics platform, from BioInsights LLC through a $30 million equity transaction.
- The transaction grants Profusa exclusive access to the PanOmics technology, with BioInsights receiving a 3% royalty on net revenues and the ability to nominate a board member.
- Profusa modified its current financing structure, releasing new senior secured convertible notes totaling up to $12.2 million to support operational needs.
- The firm is partnering with Mayo Clinic on its Lumee oxygen monitoring system for pancreatic surgery applications, representing a potential $26 million yearly revenue stream.
- Profusa increased its 2026 revenue projection to between $1.5M and $3M, up from the previous range of $500K to $2M, driven by heightened European distributor orders.
Profusa (PFSA) experienced a dramatic Monday trading session. The micro-cap biotechnology stock skyrocketed more than 173% after revealing a letter of intent to purchase the PanOmics multi-omics diagnostics technology from BioInsights LLC through an all-equity transaction valued at approximately $30 million.
Profusa, Inc. Common Stock, PFSA
However, investors should maintain perspective. The stock remains down approximately 99.92% over the trailing twelve months, with the company maintaining a market capitalization of only $870,000.
The letter of intent was initially executed on March 31, 2026, with subsequent amendments on April 3 and 4. The agreement would provide Profusa with exclusive rights to PanOmics’ intellectual property portfolio and diagnostic technology, which specializes in next-generation sequencing (NGS) applications for cancer testing.
According to the agreement terms, BioInsights will earn a 3% royalty on net revenues and gain the privilege to nominate one independent director for stockholder consideration. BioInsights will additionally provide clinical sample access to support platform validation efforts.
The acquisition requires shareholder approval, completion of due diligence, and regulatory clearance before finalization. Profusa has indicated plans to secure an additional $10 million through equity financing to support PanOmics validation activities and equipment purchases.
Strategic Rationale Behind PanOmics Acquisition
The acquisition’s timing aligns with recent CMS reimbursement developments supporting NGS-based oncology diagnostics, which Profusa believes creates a significant commercial opportunity. The transaction aims to broaden revenue streams while the company’s primary LumeeOxygen product undergoes clinical validation.
CEO Dr. Ben Hwang characterized the transaction as introducing $30 million in stockholder equity to the balance sheet while establishing the company’s presence in precision diagnostics. Management teams will receive new equity compensation equal to 12% of fully diluted shares, creating alignment with the expanded technology platform.
The transaction framework includes issuing both common and non-voting preferred stock, with a seven-year lock-up restriction applied to the majority of BioInsights’ equity position.
Mayo Clinic Partnership and Financial Projections
Independently from the acquisition, Profusa is collaborating with Mayo Clinic to deploy its Lumee oxygen monitoring technology in pancreatic surgical procedures. The company calculates that over 13,000 pancreatic resections occur annually across the United States, representing a potential $26 million annual revenue market.
Regarding financing activities, Profusa revised its securities purchase agreement on April 2, allowing the company to issue up to $12.2 million in additional senior secured convertible notes. A third-tranche note worth $555,555.55 was issued to Ascent Partners Fund, with a 2027 maturity date, accompanied by a warrant for 1,111,111 common shares priced at $0.50.
The company also recently abandoned a planned $15 million public offering in preference of a more modest capital raise, and discontinued its Bitcoin treasury reserve initiative, selling all Bitcoin positions.
Profusa has elevated its full-year 2026 revenue guidance to between $1.5 million and $3 million, compared to the previous estimate of $500,000 to $2 million, attributing the increase to expanded purchase orders from European distributors for the Lumee monitoring system.
